# Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
Canonical URL: https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6
Ticker: TSHA
Company: Taysha Gene Therapies
Source: Taysha Gene Therapies
Published: 2026-04-29 12:00 EST
Original Source URL: https://ir.tayshagtx.com
## Summary

DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today

## Article Body
DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today
## Recent Company News
- 2026-05-06 12:00 EST — [Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Taysha Gene Therapies
- 2026-05-01 20:05 EST — [Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Taysha Gene Therapies
- 2026-04-29 12:00 EST — [Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-to-release-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-6) — Source: Taysha Gene Therapies
- 2026-04-27 21:22 EST — [Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-to-present-new-preclinical-data-supporting-construct-design-of-tsha-102-for-rett-syndrome-at-the-asgct-2026-annual-meeting) — Source: Taysha Gene Therapies
- 2026-03-19 12:00 EST — [Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-reports-full-year-2025-financial-results-and-provides-corporate-update) — Source: Taysha Gene Therapies
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)